You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

IGF-1 receptor inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal Trial in Los Angeles, Bethesda (Dasatinib, Ganitumab)

Terminated
Has Results
  • Rhabdomyosarcoma
  • +2 more
  • Los Angeles, California
  • +1 more
Mar 17, 2022

Thyroid Eye Disease Trial (VRDN-001 10 mg/kg Drug:)

Not yet recruiting
  • Thyroid Eye Disease
  • VRDN-001 10 mg/kg Drug:
  • (no location specified)
Sep 7, 2023

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Trial (Giredestrant, Fulvestrant, Abemaciclib)

Not yet recruiting
  • Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
  • (no location specified)
Sep 26, 2023

Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma Trial in Boston,

Active, not recruiting
  • Estrogen Receptor-positive Breast Cancer
  • +5 more
  • PI3K inhibitor BYL719
  • +3 more
  • Boston, Massachusetts
  • +1 more
Oct 14, 2022

Breast Cancer Trial in Canton (TTI-101, Palbociclib, Aromatase inhibitor (AI))

Recruiting
  • Breast Cancer
  • Saint Louis, Missouri
  • +2 more
Jan 12, 2023

Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer Trial (BGB-43395, Fulvestrant, Letrozole)

Not yet recruiting
  • Advanced Solid Tumor
  • +8 more
  • (no location specified)
Nov 13, 2023

Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in

Recruiting
  • Malignant Pleural Mesothelioma, Advanced
  • Oncolytic Adenovirus H101
  • Programmed death receptor-1 inhibitor
  • Tianjin, Tianjin, China
    Tianjin Medical Unversity Second Hospital
Sep 2, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (BTK inhibitor, PD-1 inhibitor)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • BTK inhibitor
  • PD-1 inhibitor
  • Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
May 20, 2023

Head Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Oral Cavity Squamous Cell Carcinoma Trial in Nashville

Not yet recruiting
  • Head and Neck Cancer
  • +9 more
  • Nashville, Tennessee
    Vanderbilt-Ingram Cancer Center
Aug 9, 2022

Acne Vulgaris Trial in Stanford (Clascoterone 1% Top Cream, Vehicle)

Not yet recruiting
  • Acne Vulgaris
  • Stanford, California
    Stanford University
Jun 6, 2023

Kidney Transplant Recipients Trial in Toronto (Dapagliflozin 10 MG, Semaglutide, 1.0 mg/mL)

Not yet recruiting
  • Kidney Transplant Recipients
  • Dapagliflozin 10 MG
  • Semaglutide, 1.0 mg/mL
  • Toronto, Ontario, Canada
    Toronto General Hospital
Jul 6, 2023

Cancer Trial in United States (JTX-4014)

Active, not recruiting
  • Cancer
  • Denver, Colorado
  • +3 more
Sep 9, 2022

ST Elevation Myocardial Infarction Trial in Geneva (Successful primary PCI, defined as primary PCI of the culprit lesion with =1

Not yet recruiting
  • ST Elevation Myocardial Infarction
  • Successful primary PCI, defined as primary PCI of the culprit lesion with ≥1 Abluminus NP polymer-free sirolimus-based nanocarrier eluting stent (Concept Medical Inc., India) implantation
  • Geneva, Switzerland
    Geneva University Hospitals
Mar 25, 2023

Breast Cancer, Hormone Receptor Positive Tumor Trial in Tampa (Durvalumab, Anastrozole 1mg, Letrozole 2.5mg)

Terminated
Has Results
  • Breast Cancer
  • Hormone Receptor Positive Tumor
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
May 27, 2022

Comparative Effectiveness of Empagliflozin in the US

Active, not recruiting
  • Diabetes Mellitus, Type 2
  • Boston, Massachusetts
    Bringham Women Hospital
Jan 9, 2023

Non Small Cell Lung Cancer, Solid Tumor Trial in Fairfax (BBP-398 with nivolumab)

Recruiting
  • Non Small Cell Lung Cancer
  • Solid Tumor
  • BBP-398 with nivolumab
  • Springdale, Arkansas
  • +6 more
Jan 27, 2023

Relapsed/ Refractory Multiple Myeloma Trial in Worldwide (Talquetamab, Teclistamab, PD-1 Inhibitor)

Recruiting
  • Relapsed/ Refractory Multiple Myeloma
  • Denver, Colorado
  • +19 more
Jan 27, 2023

Urothelial Carcinoma Trial in Shanghai (AZD4547, Tislelizumab)

Recruiting
  • Urothelial Carcinoma
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 8, 2023

Thyroid Eye Disease Trial in United States (VRDN-001, Placebo)

Recruiting
  • Thyroid Eye Disease
  • Beverly Hills, California
  • +16 more
Aug 11, 2022

Colorectal Cancer, Hematologic Malignancy, Rectum Cancer Trial in Cleveland (Vactosertib, Fludarabine Phosphate,

Recruiting
  • Colorectal Cancer
  • +11 more
  • Cleveland, Ohio
    University Hospitals Cleveland Medical Center, Case Comprehensiv
Jan 18, 2023

Carcinoma, Ductal, Breast, Breast Cancer, Breast Tumor Trial in Worldwide (G1T38, Fulvestrant)

Active, not recruiting
  • Carcinoma, Ductal, Breast
  • +2 more
  • Sofia, Bulgaria
  • +7 more
Aug 1, 2022

Rectal Cancer Trial in New York (Etrumadenant (AB928), Radiation therapy, FOLFOX regimen)

Recruiting
  • Rectal Cancer
  • Etrumadenant (AB928)
  • +3 more
  • New York, New York
  • +2 more
Apr 10, 2022

Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Tumor Trial in

Suspended
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
May 23, 2022

Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer, HER2-Negative Breast Cancer, Metastatic Epithelial Ovarian Cancer

Terminated
  • Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer
  • +2 more
  • Boston, Massachusetts
  • +2 more
Mar 16, 2022

Ovarian Cancer Trial in Maywood (Decitabine, Carboplatin, Paclitaxel)

Not yet recruiting
  • Ovarian Cancer
  • Maywood, Illinois
    Loyola University Medical Center
Aug 1, 2023